Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)
A

2020 SOHO Highlights on Fitness in CLL: What Is the Role of Comorbidities and Age? Are Ibrutinib & Venetoclax More Beneficial in Younger Patients?

By Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020) FEATURING Alessandra Tedeschi
By Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020) FEATURING Alessandra Tedeschi
202 views
October 20, 2020
SOHO 2020 on-demand content is available through January 12, 2021. To access the virtual environment, ...
read more ↘
0 Comments
Login to view comments. Click here to Login

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay

Related Content

AUTOPLAY
12:47
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Summary: "Experts Discuss Key Abstracts in CLL"

Feat. S. O'Brien, C. Coombs
17:05
Cleveland Clinic Taussig Cancer Institute

Frontline CLL Learnings From Phase 3 RESONATE-2, iLLUMINATE, and E19…

Feat. A. Winter
08:17
Adam Kittai

Highlights From iwCLL 2023: What's New and Practice Informing i…

06:56
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Efficacy of Ibrutinib Arms Across ALPINE an…

Feat. M. Shadman
15:21
5th SOHO Italy Annual Conference

SOHO Italy 2023: How I Treat CLL at the MD Anderson Cancer Center

Feat. A. Ferrajoli
08:45
Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "The Best of CLL - Highlights & Key Takea…

Feat. V. Yazbeck
06:28
Insights from 2023 EHA® Annual Meeting

EHA® 2023 Insights: "Venetoclax + Obinutuzumab for Previously U…

Feat. O. Al-Sawaf
06:21
City of Hope

Cardiac Safety of Zanubrutinib vs. Other BTKis in CLL

Feat. A. Danilov
18:01
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "MRD-Directed Therapy in CLL - Ready for Pri…

Feat. J. Rhodes
11:39
5th SOHO Italy Annual Conference

SOHO Italy 2023: Current Approach to Sequencing CLL Therapy in the R…

Feat. G. Gaidano
10:19
Alvaro Alencar

Pirtobrutinib in R/R CLL

05:12
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Fixed-Duration Pirtobrutinib Combined With …

Feat. N. Shah
17:21
Daniel Addison

Cardiovascular Considerations With (Contemporary) BTKi in the Treatm…

10:22
SOHO 2023 Eleventh Annual Meeting

SOHO 2023 Next Questions: CLL

Feat. N. Jain
28:43
Scripps MD Anderson Cancer Center Clinical Hematology & Oncology 2023

Scripps MD Anderson Cancer Center Updates on CLL/SLL Frontline Thera…

Feat. S. O'Brien
06:59
Constantine Tam

A Matching-Adjusted Indirect Comparison of Zanubrutinib vs. Acalabru…

08:26
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Pirtobrutinib in Post-cBTKi CLL/SLL - 30 Mo…

Feat. J. Woyach
10:35
Alan Skarbnik

Learnings From the ELEVATE-TN Phase 3 Trial: Acalabrutinib+/-Obinutu…

16:16
Insights from 2023 EHA® Annual Meeting

Experts Discuss Key Updates in CLL From EHA and iCML

Feat. S. O'Brien, C. Coombs
20:58
Andrew Lipsky

Recent Updates on the Use of BTK Inhibitors in CLL